Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines

References

• Greenwood B. The contribution of vaccination to global health: past, present and future. Phil Trans R Soc B. 2014;369:20130433. doi:10.1098/rstb.2013.0433.
   PubMed Web of Science ®Google Scholar
• Cherry JD. Historical review of pertussis and the classical vaccine. J Infect Dis. 1996;174(Suppl 3):S259–10. doi:10.1093/infdis/174.supplement_3.s259.
   PubMedGoogle Scholar
• Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29:449–86. doi:10.1128/CMR.00083-15.
   PubMed Web of Science ®Google Scholar
• Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents and adults: a systematic review of epidemiology and mortality in Europe. Infect Dis Ther. 2021;10(4):2071–118. doi:10.1007/s40121-021-00520-9.
   PubMed Web of Science ®Google Scholar
• WHO. SAGE pertussis working group: background paper. SAGE; 2014 Apr [accessed 2023 Nov 27]. https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Apr2014/8_session_pertussis/Apr2014_session8_pertussis.pdf.
   Google Scholar
• Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013;368(6):581–2. doi:10.1056/NEJMc1212006.
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454–6. Erratum in: JAMA. 2012;308:1432. doi:10.1001/jama.2012.6364.
   PubMed Web of Science ®Google Scholar
• Wanlapakorn N, Ngaovithunvong V, Thongmee T, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Seroprevalence of antibodies to pertussis toxin among different age groups in Thailand after 37 years of universal whole-cell pertussis vaccination. PLOS ONE. 2016;11(2):e0148338. doi:10.1371/journal.pone.0148338.
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B vaccine among Thai children at 18-19 months of age. Southeast Asian J Trop Med Public Health. 2012;43:442–54.
   PubMed Web of Science ®Google Scholar
• Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18–19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children. Southeast Asian J Trop Med Public Health. 2012;43:687–98.
   PubMed Web of Science ®Google Scholar
• Szwejser-Zawislak E, Wilk MM, Piszczek P, Krawczyk J, Wilczyńska D, Hozbor D. Evaluation of whole-cell and acellular pertussis vaccines in the context of long-term herd immunity. Vaccines. 2022;11:1. doi:10.3390/vaccines11010001.
   Web of Science ®Google Scholar
• Rieber N, Graf A, Belohradsky BH, Hartl D, Urschel S, Riffelmann M, Wirsing von König C-H, Liese J. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination. Vaccine. 2008;26(52):6929–35. doi:10.1016/j.vaccine.2008.09.064.
   PubMed Web of Science ®Google Scholar
• Diks AM, Versteegen P, Teodosio C, Groenland RJ, de Mooij B, Buisman AM, Torres-Valle A, Pérez-Andrés M, Orfao A, Berbers GAM, et al. On behalf of the Imi-Periscope consortium. Age and primary vaccination background influence the plasma cell response to pertussis booster vaccination. Vaccines. 2022;10(2):136. doi:10.3390/vaccines10020136.
   Google Scholar
• Wanlapakorn N, Maertens K, Vongpunsawad S, Puenpa J, Tran TMP, Hens N, Van Damme P, Thiriard A, Raze D, Locht C, et al. Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial. Clin Infect Dis. 2020;71(1):72–80. doi:10.1093/cid/ciz778.
   PubMed Web of Science ®Google Scholar
• Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1–44. doi:10.15585/mmwr.rr6702a1.
   PubMed Web of Science ®Google Scholar
• Slack MPE, Cripps AW, Grimwood K, Mackenzie GA, Ulanova M. Invasive Haemophilus influenzae infections after 3 decades of hib protein conjugate vaccine use. Clin Microbiol Rev. 2021;34(3):e0002821. doi:10.1128/CMR.00028-21.
   PubMed Web of Science ®Google Scholar
• Wanlapakorn N, Maertens K, Thongmee T, Srimuan D, Thatsanathorn T, Van Damme P, Leuridan E, Poovorawan Y. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine. 2020;38(44):6914–21. doi:10.1016/j.vaccine.2020.08.058.
   PubMed Web of Science ®Google Scholar
• Acosta AM, Wharton M. Diphtheria toxoid. In: Orenstein W; Offit P; Edwards K Plotkin S. editors. Plotkin’s Vaccines. 8th ed. Philadelphia: Elsevier; 2023. Chapter21, 298–310.e8. doi:10.1016/C2019-0-00240-3.
   Google Scholar
• World health organization vaccine-preventable diseases surveillance standards: annex 2 tetanus serosurveys; 2018 Sept 5 [Accessed 2024 Apr 22]. https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-annex2.
   Google Scholar
• Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063–8. doi:10.1016/S0140-6736(99)04377-9.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:129. Erratum in: Nat Rev Immunol. 2021 Feb;21:83–100. 10.1038/s41577-020-00479-7.
   Web of Science ®Google Scholar
• van der Lee S, Hendrikx LH, Sanders EAM, Berbers GAM, Buisman AM. Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles. Front Immunol. 2018;9:51. doi:10.3389/fimmu.2018.00051.
   PubMed Web of Science ®Google Scholar
• Podda A, Bona G, Canciani G, Pistilli AM, Contu B, Furlan R, Meloni T, Stramare D, Titone L, Rappuoli R, et al. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian multicenter group for the study of recombinant acellular pertussis vaccine. J Pediatr. 1995;127(2):238–43. doi:10.1016/s0022-3476(95)70301-2.
   PubMed Web of Science ®Google Scholar
• Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin. 2008;4(3):203–9. doi:10.4161/hv.4.3.5290.
   PubMed Web of Science ®Google Scholar
• Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, et al. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine. 2007 Jan 22;25(6):1121–5. doi:10.1016/j.vaccine.2006.09.053.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics. 2000;105(1):e11. doi:10.1542/peds.105.1.e11.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Updates on immunologic correlates of vaccine-induced protection. Vaccine. 2020;38(9):2250–7. doi:10.1016/j.vaccine.2019.10.046.
   PubMed Web of Science ®Google Scholar
• Abu Raya B, Srugo I, Kessel A, Peterman M, Vaknin A, Bamberger E. The decline of pertussis-specific antibodies after tetanus, diphtheria, and acellular pertussis immunization in late pregnancy. J Infect Dis. 2015;212:1869–73. doi:10.1093/infdis/jiv324.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Langley JM, Ye L, MacKinnon-Cameron D, Elsherif M, Allen VM, Smith B, Halperin BA, McNeil SA, Vanderkooi OG, et al. A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response. Clin Infect Dis. 2018;67(7):1063–71. doi:10.1093/cid/ciy244.
   PubMed Web of Science ®Google Scholar
• Maertens K, Hoang TT, Nguyen TD, Caboré RN, Duong TH, Huygen K, Hens N, Van Damme P, Dang DA, Leuridan E. The effect of maternal pertussis immunization on infant vaccine responses to a booster pertussis-containing vaccine in Vietnam. Clin Infect Dis. 2016;63(suppl 4):S197–S204. doi:10.1093/cid/ciw551.
   PubMed Web of Science ®Google Scholar
• Maertens K, Caboré RN, Huygen K, Vermeiren S, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. Vaccine. 2016;34(31):3613–9. doi:10.1016/j.vaccine.2016.04.066.
   PubMed Web of Science ®Google Scholar
• Sapuan S, Andrews N, Hallis B, Hole L, Jones CE, Matheson M, Miller E, Snape MD, Heath PT. An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-containing vaccines or received no pertussis-containing vaccine in pregnancy in England. Vaccine. 2022;40(49):7050–6. 10.1016/j.vaccine.2022.10.005.
   PubMed Web of Science ®Google Scholar
• Madhi SA, López P, Zambrano B, Jordanov E, B’Chir S, Noriega F, Feroldi E. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019;15(3):658–68. doi:10.1080/21645515.2018.1546524.
   PubMed Web of Science ®Google Scholar
• Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV). Hum Vaccin. 2010;6(7):554–61. doi:10.4161/hv.6.7.11760.
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J. 2002;21(6):535–41. doi:10.1097/00006454-200206000-00011.
   PubMed Web of Science ®Google Scholar
• Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, Goldblatt D, Miller E. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14(10):1328–33. doi:10.1128/CVI.00191-07.
   PubMedGoogle Scholar
• Chen Z, He Q. Immune persistence after pertussis vaccination. Hum Vaccin Immunother. 2017;13(4):744–56. doi:10.1080/21645515.2016.1259780.
   PubMed Web of Science ®Google Scholar